Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462786 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01462786 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT01462786, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to compare the pharmacokinetic profile of ATX-101 administered into subcutaneous fat in the submental area and abdomen.
Interventions
- DRUG ATX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462786
The ClinicalTrials.gov registry entry for NCT01462786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATX-101 is the first listed.
NCT01462786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462786 about?
NCT01462786 is a clinical study titled "To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101". The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to compare the pharmacokinetic profile of ATX-101 administered into subcutaneous fat in the submental area and abdomen.
What is the current status of trial NCT01462786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2011-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01462786?
The interventions under investigation include: ATX-101 (DRUG).
Who is sponsoring clinical trial NCT01462786?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.